Codexis (CDXS) Upgraded to Strong-Buy by BidaskClub
Codexis (NASDAQ:CDXS) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Saturday.
Other analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $8.50 price target on shares of Codexis in a research report on Tuesday, November 21st. Zacks Investment Research raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Codexis currently has an average rating of “Buy” and a consensus price target of $8.58.
Codexis (CDXS) opened at $10.40 on Friday. Codexis has a 1-year low of $3.85 and a 1-year high of $10.75. The company has a market cap of $502.81, a price-to-earnings ratio of -16.00 and a beta of -1.60.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.